Indranil Bhattacharya - Takeda Development Center Americas, Inc

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura

Marie Scully,Ana Antun,Spero R. Cataland,Paul Coppo,Claire Dossier,Nathalie Biebuyck,Wolf-Achim Hassenpflug,Karim Kentouche,Paul Knoebl,Johanna A. Kremer Hovinga, M. Fernanda Lopez-Fernandez,Masanori Matsumoto,Thomas L. Ortel,Jerzy Windyga,Indranil Bhattacharya, Michael Cronin,Hong Li,Bjorn Mellgard,Munjal Patel,Parth Patwari, Shan Xiao, Pinghai Zhang,Linda T. Wang

NEW ENGLAND JOURNAL OF MEDICINE（2024）

引用0浏览0WOS引用

Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers

Mariam A Ahmed,Rajesh Krishna, Noha Rayad,Salwa Albusaysi,Amitava Mitra, Elizabeth Shang,Yuen Yi Hon,Bilal AbuAsal,Rana Bakhaidar,Youssef M Roman,Indranil Bhattacharya,James Cloyd,Munjal Patel,Reena V Kartha,Islam R Younis

Clinical pharmacology and therapeuticsno. 6 (2024): 1412-1432

引用0浏览0WOS引用

Exposure–Response Relationship Between VWF/FVIII Activity and Spontaneous Bleeding Events Following Recombinant VWF Prophylaxis in Severe VWD

Frank W G Leebeek,Giancarlo Castaman,Jean François Marier,Gülden Özen,Indranil Bhattacharya,Jingmei Zhang,Scarlett Wang,Yi Wang

TH openno. 02 (2024): e243-e251

引用0浏览0WOS引用

Population Pharmacokinetics and Exposure-Response Analyses to Demonstrate the Link of Causality Between ADAMTS13 and the Clinical Effects of Recombinant ADAMTS13 Compared to Plasma-Based Therapies

Munjal Patel, Olivier Barriere, Paul Diderichsen, Huijuan Xu,Andy Zhu,Jean Francois Marier,Bjorn Mellgard, Wenping Wang,Indranil Bhattacharya

Bloodno. Supplement 1 (2023): 1260-1260

引用0浏览0引用

Pharmacokinetics (PK), Pharmacodynamics (PD), and Exposure-Response (E-R) Analyses Confirm the Effectiveness of Lanadelumab in Patients 2 to <12 Years Old with Hereditary Angioedema (HAE)

Mariam Ahmed,Yi Wang,Ming Yu,Jean-Francois Marier,Indranil Bhattacharya

Journal of Allergy and Clinical Immunology（2023）

引用0浏览0引用

Approval of Drugs with Unmet Trial End Points

Indranil Bhattacharya, Iraj Daizadeh, Alan Robertson

JAMA internal medicineno. 8 (2023): 889-889

引用0浏览0引用

Quantitative System Pharmacology Modeling of the Effect of Recombinant ADAMTS13 on Platelets in Patients with Congenital Thrombotic Thrombocytopenic Purpura

Cameron McBride, Jiaolong Jiang,Zhiwei Zhang,John Tolsma,Bjorn Mellgard,Majid Vakilynejad,Indranil Bhattacharya,Andy Zhu

Bloodno. Supplement 1 (2023): 5517-5517

引用0浏览0引用

Exposure-Response Relationship Between Von Willebrand Factor (VWF) Activity and Bleeding Events Following Prophylaxis with Recombinant VWF (rvwf, Vonicog Alfa) in Patients with Severe Von Willebrand Disease (VWD)

Yi Wang,Gulden Ozen,Bjorn Mellgard,Jean Francois Marier, Olivier Barriere,Grygoriy Vasilinin,Indranil Bhattacharya

Blood（2021）

引用0浏览0引用

Recombinant ADAMTS13 for Patients with Sickle Cell Disease: Design of a Phase 1 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study

Parth Patwari,Van Anh (Vika) Nguyen,Indranil Bhattacharya,Nisha Jain

BLOOD（2021）

引用1浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn